An observational study in Alzheimer s Disease, TDP-43 Proteinopathies and MCI, sponsored by Central Hospital, Nancy, France. Not yet recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Central Hospital, Nancy, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alzheimer Disease by Central Hospital, Nancy, France — 9 open to participants now, 9 under way, none of them phase 3. Alzheimer Disease · Central Hospital, Nancy, France.
Among the 17 studies in Alzheimer Disease by Central Hospital, Nancy, France, this one is one of 2 that started in 2026, is one of 8 observational ones, and was the 17th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →9 of the 17 studies in Alzheimer Disease by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18–99
Central Hospital, Nancy, France · Sites in France
Ages 18–80
Central Hospital, Nancy, France · Sites in France
Central Hospital, Nancy, France · Sites in France
Ages 25–65 · Healthy volunteers
Central Hospital, Nancy, France · Sites in France
Ages 60+
By country, each count listing its studies:
Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 500 is above the median of 200 across 816 observational studies indexed under Alzheimer Disease.
Median enrollment 77 across the 9 interventional studies, 65 across the 8 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
3 of the studies in Alzheimer Disease by Central Hospital, Nancy, France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07309107Central Hospital, Nancy, FranceDeep Learning on Amyloid Positons Emission Tomography | 2026-11-20 |
| NCT07947446Central Hospital, Nancy, FranceCHUCOLATE: Current Knowledge and Prevalence of LATE-NC in Geriatric Memory Clinics at a Memory Center in Lorraine | 2026-12-31 |
| NCT06825663Central Hospital, Nancy, FranceMarker of Brain Insulin Resistance in AD Prognosis | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Alzheimer Disease by Central Hospital, Nancy, France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
LATE syndrome (Limbic-predominant Age-related TDP-43 Encephalopathy) is a neurocognitive disorder associated with TDP-43 proteinopathy, whose clinical presentation-a hippocampal amnestic syndrome-is similar to that of Alzheimer's disease. There are no specific markers to differentiate between the two, other than the exclusion of Alzheimer's biomarkers (AB), a criterion limited by the possibility of comorbidity. In the era of anti-amyloid therapies, it is crucial to differentiate between them in order to appropriately offer these therapies to patients. The clinical diagnosis of LATE is therefore of great importance. A pattern specific to LATE has been described on PET-CT and may facilitate this diagnosis.
To study the concordance between the PET-CT pattern and the clinical criteria for LATE, we will compare changes in MMSE scores over one year between patients classified as "LATE" or "AD" based on 18F-FDG PET-CT.
The study population consists of patients who underwent a PET-CT scan between 2020 and 2026 as part of the diagnostic evaluation for neurocognitive disorders at the Geriatric Research Center (CMRR) of the Nancy University Hospital (CHRU)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
MMSE score
MMSE score
Time frame: 1 year
memory score
memory score on psychometric test
Time frame: 1 year
Plan to share: Undecided
Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →